Amylin Receptor Signaling in the Nucleus Accumbens Negatively Modulates μ-opioid-driven Feeding
Overview
Authors
Affiliations
Amylin is a peptide co-secreted with insulin that penetrates into the brain, and produces satiation-like effects via actions in the brainstem, hypothalamus, and mesencephalon. Little is known, however, about the effects of amylin in the nucleus accumbens shell (AcbSh), where a circumscribed zone of intense amylin receptor (AMY-R) binding overlaps reported mappings of a 'hotspot' for μ-opioid receptor (μ-OR) amplification of food reward. Here, the ability of intra-AcbSh AMY-R signaling to modulate μ-OR-driven feeding was explored. Amylin (1-30 ng) was administered with the μ-OR agonist, D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) (0.25 μg), directly into the AcbSh of ad libitum-maintained rats. Amylin dose-dependently reversed DAMGO-induced hyperphagia; 3 ng of amylin reduced DAMGO-mediated feeding by nearly 50%. This dose was, however, completely ineffective at altering DAMGO-induced feeding in the anterior dorsal striatum. Intra-AcbSh amylin alone (3-30 ng) modestly suppressed 10% sucrose intake in ad libitum-maintained rats, and chow in food-deprived rats, but only at the 30-ng dose. This result indicates that reversal of AcbSh DAMGO-induced feeding at a 10-fold lower dose was neither due to malaise nor motoric impairment. Finally, intra-AcbSh infusion of the AMY-R antagonist, AC187 (20 μg), significantly attenuated the ability of prefeeding to suppress DAMGO-induced food intake, with no effects in non-prefed rats. Hence, AMY-R signaling negatively modulates μ-OR-mediated appetitive responses at the level of the AcbSh. The results with AC187 indicate that endogenous AMY-R transmission in the AcbSh curtails opioid function in the postprandial period, suggesting a novel pathway for peripheral-central integration in the control of appetitive motivation and opioid reward.
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.
Jerlhag E Endocrinology. 2025; 166(4).
PMID: 39980336 PMC: 11879929. DOI: 10.1210/endocr/bqaf028.
Jerlhag E Front Pharmacol. 2023; 14:1063033.
PMID: 37063267 PMC: 10097922. DOI: 10.3389/fphar.2023.1063033.
Gotteland M, Zazueta A, Pino J, Fresard A, Sambra V, Codoceo J Foods. 2023; 12(4).
PMID: 36832775 PMC: 9955387. DOI: 10.3390/foods12040700.
Tufvesson-Alm M, Shevchouk O, Jerlhag E Front Psychiatry. 2023; 13:1092828.
PMID: 36699502 PMC: 9868418. DOI: 10.3389/fpsyt.2022.1092828.
Macronutrient intake: Hormonal controls, pathological states, and methodological considerations.
Przybysz J, DiBrog A, Kern K, Mukherjee A, Japa J, Waite M Appetite. 2022; 180:106365.
PMID: 36347305 PMC: 10563642. DOI: 10.1016/j.appet.2022.106365.